Genesee Capital Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Genesee Capital Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-421	Closed	-$1.58K	–	99
2023 Q1	$1.58K	Sell	421 -241	-36%	-$1.26K	﹤0.01%	86
2022 Q4	$2.05K	Hold	662	–	–	﹤0.01%	78
2022 Q3	$3K	Hold	662	–	–	﹤0.01%	84
2022 Q2	$17K	Hold	662	–	–	0.01%	92
2022 Q1	$25K	Hold	662	–	–	0.01%	108
2021 Q4	$39K	Hold	662	–	–	0.02%	109
2021 Q3	$54K	Buy	+662	New	+$57.5K	0.03%	112

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Genesee Capital Advisors's VTGN Position: Q2 2023 in Review

Genesee Capital Advisors sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 421 shares — an estimated $1.58K sold.

Genesee Capital Advisors first reported a position in VTGN in Q3 2021 and held it in 7 quarters. The position peaked at $54K in Q3 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

Genesee Capital Advisors reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
Genesee Capital Advisors sold 421 VistaGen Therapeutics shares in Q2 2023, an estimated $1.58K.
Genesee Capital Advisors first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 7 quarters.
Genesee Capital Advisors's VistaGen Therapeutics position peaked at $54K in Q3 2021.
33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Genesee Capital Advisors's 13F filing for Q2 2023, filed 17 Jul 2023.